Institute for Neurosciences, Algesiology and Pediatrics (IFNAP)

This sponsor has funded 10 studies across 1 countries.

PAS funded by this sponsor.
EU PAS ID Status RMP requirement Title Protocol uploaded Results uploaded
11234 Ongoing Unspecified NON-INTERVENTIONAL OBSERVATIONAL STUDY FOR THE EVALUATION OF TOLERABILITY AND EFFICACY OF THE WHO-STEP III OPIOIDS OXYCODONE/NALOXONE PR AND... No No
12247 Finalised Unspecified EFFICACY, TOLERABILITY AND SAFETY OF AN ORAL ENZYME COMBINATION VS. DICLOFENAC IN OSTEOARTHRITIS OF THE KNEE – RESULTS OF AN INDIVIDUAL PATIENT-LEVEL... No No
25799 Planned Not included in RMP Effectiveness and tolerability of the THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label... No No
33014 Planned Not included in RMP Effectiveness and tolerability of the THC:CBD oromucosal spray vs. dronabinol as add-on measure in patients with severe neuropathic pain:... No No
38969 Planned Not included in RMP Effectiveness and tolerability of the THC:CBD oromucosal spray vs. typical oral long-term opioid-analgesics in patients with severe neuropathic (low)... No No
42286 Finalised Not included in RMP Prevalence of drug-induced constipation and severity of associated biopsychosocial effects in patients with nonmalignant pain. A cross-sectional... No No
44365 Finalised Not included in RMP Biopsychosocial characteristics of patients with fibromyalgia / chronic widespread pain. A cross-sectional review of depersonalized data from the... No No
50135 Finalised Not included in RMP Bio-psycho-social characteristics of patients with migraine. A cross-sectional review of depersonalized data from the German Pain e-Registry. (BIOMIC) No No
105823 Finalised Not included in RMP Fremanezumab versus conventional preventive treatments as ≥2nd line prophylaxis of migraine – propensity score matched multiple cohort comparative... No No
106076 Finalised Not included in RMP Eptinezumab versus conventional preventive treatments as ≥2nd line prophylaxis of migraine – propensity score matched multiple cohort comparative... No No

PAS by Risk Management Plan (RMP) requirement

Institute for Neurosciences, Algesiology and Pediatrics (IFNAP)

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.